Neurocognitive changes in cancer survivors

Cancer Journal

Volumn 14, Issue 6, 2008, Pages 396-400

  Correa, Denise D ^a   Ahles, Tim A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Chemotherapy; Cognitive functions

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; TAMOXIFEN; THIOTEPA;

ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; INTRADUCTAL CARCINOMA; LYMPHOMA; MEDICAL LITERATURE; MEMORY DISORDER; MOUSE; NEUROIMAGING; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DIAGNOSTIC IMAGING; FEMALE; HUMANS; PROSPECTIVE STUDIES; SURVIVORS;

EID: 58149215663     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31818d8769     Document Type: Article

References (36)

1. Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet. 2004;3:1-18.
2. Correa DD. Cognitive functions in brain tumor patients. Hematol Oncol Clin North Am. 2006;20:1363-1376.
3. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995;4:61-66.
4. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. [comment]. J Natl Cancer Inst. 1998;90:210-218.
5. Schagen SB, van Dam FS, Muller MJ, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85:640-650.
6. Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002;13:1387-1397.
7. Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000; 18:2695-2701.
8. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychological impact of standard-dose chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485-493.
9. Tchen M, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003;21:4175-4183.
10. Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955-969.
11. Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fogmethodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2006;95:125-129.
12. Donovan KA, Small BJ, Andrykowski MA, et al. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early stage breast carcinoma. Cancer. 2005;104:2499-2507.
13. Scherwath A, Mehnert A, Schleimer B, et al. Neuropsychological function in high risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term effects. Ann Oncol. 2006;17:415-423.
14. Vardy J, Wefel JS, Ahles TA, et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2007;19:623-629.
15. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7:192-201.
16. Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004; 100:2292-2299.
17. Schilling V, Jenkins V, Morris R, et al. The effects of adjuvant chemotherapy on cognition in women with breast cancer-preliminary results of an observational study. Breast. 2005;14:142-150.
18. Hurria A, Rosen C, Hudis C, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006;54:925-931.
19. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94:828-834.
20. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006;15:422-430.
21. Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study [published online ahead of print July 16, 2008]. Breast Cancer Res Treat.
22. Collins B, Mackenzie J, Stewart A, et al. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment [published online ahead of print June 12, 2008]. Psychooncology.
23. Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapyinduced cognitive disorders: neuropsychological, pathophysiological and neuroimaging perspectives. Semin Clin Neuropsychiatry: 2003:8: 201-216.
24. Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109:146-156.
25. Abraham J, Haut MW, Moran MT, et al. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer. 2008;8:88-91.
26. Saykin AJ, McDonald BC, Ahles TA, et al. Altered brain activation following systemic chemotherapy for breast cancer: interim analysis from a prospective study. Presented at the 34th Annual Meeting of the International Neuropsychological Society, Boston, MA, February 3, 2006.
27. Ferguson RJ, McDonald BC, Saykin AJ, et al. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25:3866-3870.
28. Silverman DHS, Dy CJ, Castellon SA, et al. Altered frontocortical. cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat. 2006;103:303-311.
29. Winocur G, Vardy J, Binns MA, et al. The effects of anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav. 2006;85:66-75.
30. Reiriz AB, Reolon GK, Roesler R, et al. Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. Clin Cancer Res. 2006;12:5000.
31. Konat GW, Krapulski M, James I, et al. Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis. 2008;23:325-333.
32. Lee GD, Longo DL, Wang Y, et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapv. Clin Cancer Res. 2006;12:198-205.
33. Dietrich J, Han R, Yang Y, et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and vivo. J Biol. 2006;5:1-23.
34. Rzeski W, Pruskil S, Macke A, et al. Anticancer agents are potent neurotoxins in vitro and in vivo. Ann Neurol. 2004;56:351-360.
35. Han R, Yang YM, Dietrich J, et al. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol. 2008;7:12.
36. Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev. 2008;18:121-131.